International consensus updates CAR T-cell therapy guidelines for severe autoimmune diseases

An international group of 31 experts has updated consensus recommendations for the use of CAR T-cell therapy in severe, treatment-refractory autoimmune diseases, reflecting growing clinical experience and expanding indications beyond cancer.

Why it matters. These updated guidelines will help ensure consistent and safe clinical practice for a new therapeutic approach in autoimmune diseases, while emphasizing the need for long-term follow-up and data collection.